Literature DB >> 19337821

Encouraging the move towards predictive population models for the obese using propofol as a motivating example.

Sarah C McLeay1, Glynn A Morrish, Carl M Kirkpatrick, Bruce Green.   

Abstract

PURPOSE: To develop a predictive pharmacokinetic model for propofol that could inform development of a dosing strategy for the obese population.
METHODS: A prior model that included a nonlinear relationship between clearance (CL) and Total Body Weight (TBW) was re-parameterized with a linear relationship between CL and Lean Body Weight (LBW). The predictive performance of both models was compared and the LBW model used to explore propofol exposure from normal to obese patients. A dosing strategy was evaluated that normalized awakening time across a range of patient weights.
RESULTS: The predictive performance of the LBW model was similar to the nonlinear TBW model for normal weighted subjects. Simulations in 70-160 kg subjects indicated that dosing linearly on TBW (label recommendation), in contrast to LBW, resulted in increased plasma concentrations in the larger weight groups. This result might explain why obese subjects take longer to awaken from anesthesia compared to normal weighted subjects. Dosing by LBW normalized patient awakening times across this weight range.
CONCLUSIONS: LBW as a covariate provides a plausible mechanistic explanation for an observed nonlinear increase in drug CL with TBW and may be suitable for developing dosing strategies that are appropriate for use in the obese population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337821     DOI: 10.1007/s11095-009-9873-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  32 in total

1.  Population pharmacokinetics of propofol in Chinese patients.

Authors:  Yu-Hong Li; Jian-Zhong Rui; Yong-Gang Zhou; Li-Qin Wang; Su-E Fu; Jian-Jun Yang; Fu-Kun Liu; Shu-Ya Hu; Quan Wen; Jian-Guo Xu
Journal:  Acta Pharmacol Sin       Date:  2003-06       Impact factor: 6.150

Review 2.  The meaning and measurement of lean body mass.

Authors:  R Roubenoff; J J Kehayias
Journal:  Nutr Rev       Date:  1991-06       Impact factor: 7.110

3.  Influence of body compartments on propofol induction dose in female patients.

Authors:  D Chassard; K Berrada; B Bryssine; M Guiraud; P Bouletreau
Journal:  Acta Anaesthesiol Scand       Date:  1996-09       Impact factor: 2.105

4.  Population pharmacokinetics of propofol: a multicenter study.

Authors:  J Schüttler; H Ihmsen
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

5.  Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia.

Authors:  A Shafer; V A Doze; S L Shafer; P F White
Journal:  Anesthesiology       Date:  1988-09       Impact factor: 7.892

6.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

7.  Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass").

Authors:  Kinichi Shibutani; Mario A Inchiosa; Keisuke Sawada; Mosses Bairamian
Journal:  Anesthesiology       Date:  2004-09       Impact factor: 7.892

8.  Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium.

Authors:  K Leslie; D I Sessler; A R Bjorksten; A Moayeri
Journal:  Anesth Analg       Date:  1995-05       Impact factor: 5.108

9.  Use of target controlled infusion to derive age and gender covariates for propofol clearance.

Authors:  Martin White; Gavin N C Kenny; Stefan Schraag
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  The use of propofol and remifentanil for the anaesthetic management of a super-obese patient.

Authors:  L La Colla; G La Colla; A Albertin; D Poli; F W Baruffaldi Preis; A Mangano
Journal:  Anaesthesia       Date:  2007-08       Impact factor: 6.955

View more
  8 in total

1.  Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

Authors:  Simone van Kralingen; Jeroen Diepstraten; Mariska Y M Peeters; Vera H M Deneer; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

2.  Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus.

Authors:  Christophe Bardin; Estelle Nobecourt; Etienne Larger; François Chast; Jean-Marc Treluyer; Saik Urien
Journal:  Eur J Clin Pharmacol       Date:  2012-01-25       Impact factor: 2.953

3.  Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusions.

Authors:  Johan Francois Coetzee
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

4.  Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size.

Authors:  Jeroen Diepstraten; Vidya Chidambaran; Senthilkumar Sadhasivam; Hope R Esslinger; Shareen L Cox; Thomas H Inge; Catherijne A J Knibbe; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

Review 5.  Assessing Renal Function for Kidney Donation. How Low Is Too Low?

Authors:  Gustavo Laham; Juan Pablo Ponti; Gervasio Soler Pujol
Journal:  Front Med (Lausanne)       Date:  2022-02-02

Review 6.  Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.

Authors:  Tine M H J Goedhart; Laura H Bukkems; C Michel Zwaan; Ron A A Mathôt; Marjon H Cnossen
Journal:  Blood Adv       Date:  2021-10-26

7.  A real-world, multicenter assessment of drugs requiring weight-based calculations in overweight, adult critically ill patients.

Authors:  Sandra L Kane-Gill; Nicholas P Wytiaz; Lisa M Thompson; Karina Muzykovsky; Mitchell S Buckley; Henry Cohen; Amy L Seybert
Journal:  ScientificWorldJournal       Date:  2013-11-30

Review 8.  Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.

Authors:  Brian L Erstad; Jeffrey F Barletta
Journal:  Crit Care       Date:  2020-06-08       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.